Esperion Therapeutics, Inc. (ESPR)

Esperion announced a definitive agreement to be acquired by ARCHIMED, leading to analyst downgrades. The company reported its First Quarter 2026 financial results, missing EPS and revenue estimates. Esperion completed the acquisition of Corstasis Therapeutics. Piper Sandler initiated coverage of Esperion with an "Overweight" rating. Esperion reported its Fourth Quarter and Full Year 2025 financial results, marking a swing to profit. Analysis indicated that Esperion was in a "holding phase" awaiting U.S. guideline inclusion.

There is no explicit information available indicating significant demand seasonality for Esperion Therapeutics, Inc.'s products and services. The company has reported consistent prescription growth and increasing physician adoption, suggesting a relatively stable demand pattern rather than seasonal fluctuations.

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing oral therapies for patients with elevated LDL-C, particularly those who are statin intolerant or resistant. The company's primary mission revolves around the commercialization of NEXLETOL (bempedoic acid) tablets, an oral, once-daily, non-statin medicine, and NEXLIZET (bempedoic acid and ezetimibe) tablets, an oral, once-daily, non-statin combination medicine. Esperion continues to investigate the potential of bempedoic acid in various patient populations and aims to develop next-generation inhibitors for multiple life-threatening diseases.

Esperion Therapeutics, Inc. is headquartered in Ann Arbor, Michigan, United States, and has a broad U.S. commercial infrastructure. Its treatments are approved in the U.S. and Europe. To maximize global reach, Esperion has established strategic collaborations with Daiichi Sankyo for commercialization rights in Europe and parts of the Middle East, and with Otsuka Pharmaceutical for the Japanese market.

In the past year, Esperion Therapeutics has generally maintained a positive reputation, particularly concerning the adoption and commercialization of its products. The company has demonstrated growing adoption of its therapies, with a 34% year-over-year increase in retail prescription equivalents and an expanded prescriber base of approximately 45,000 healthcare professionals. Esperion has also established broad payer coverage, reaching over 90% of commercial lives and Medicare beneficiaries. The recent acquisition by ARCHIMED underscores a positive valuation and confidence in Esperion's therapies.

Esperion Therapeutics, Inc. is primarily owned by institutional shareholders, who collectively hold 58.90% of the stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Wasatch Advisors Inc, Two Seas Capital LP, D. E. Shaw & Co., Inc., Orbimed Advisors Llc, State Street Corp, Geode Capital Management, Llc, Marshall Wace, Llp, and Two Sigma Investments, Lp. Target N. V. Biotech is noted as the largest individual shareholder, owning 4.48 million shares, representing 1.74% of the company.